301. 黄斑ジストロフィー Macular dystrophy Clinical trials / Disease details


臨床試験数 : 46 薬物数 : 42 - (DrugBank : 11) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 67

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04239625
(ClinicalTrials.gov)
December 20, 201911/1/2020Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt DiseaseStargardt Disease;Stargardt Macular Degeneration;Stargardt Macular Dystrophy;Autosomal Recessive Stargardt Disease 1 (ABCA4-related)Drug: ALK-001Alkeus Pharmaceuticals, Inc.NULLEnrolling by invitation8 Years70 YearsAll140Phase 2United States
2NCT02402660
(ClinicalTrials.gov)
August 20159/3/2015Phase 2 Tolerability and Effects of ALK-001 on Stargardt DiseaseA Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt DiseaseStargardt Disease;Stargardt Macular Degeneration;Stargardt Macular Dystrophy;Autosomal Recessive Stargardt Disease 1 (ABCA4-related)Drug: ALK-001;Drug: PlaceboAlkeus Pharmaceuticals, Inc.NULLRecruiting8 Years70 YearsAll140Phase 2United States
3NCT02230228
(ClinicalTrials.gov)
April 201427/8/2014Phase 1 Safety Study of ALK-001 in Healthy VolunteersA Phase 1, Open Label, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week Daily Dosing of ALK-001 in Healthy VolunteersStargardt Disease;Age-related Macular Degeneration;Other Retinal DystrophiesDrug: ALK-001 (No generic name)Alkeus Pharmaceuticals, Inc.NULLCompleted21 Years70 YearsBoth40Phase 1NULL